Physician profile
Joy Simpson Mason
NPI 1225114812
$2,797.21
in general payments reported to CMS, 2019-2025
14 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $424 · 2021: $380 · 2022: $509 · 2023: $485 · 2024: $462 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,240.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,487.36 | 2019-2024 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $241.53 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $163.37 | 2019-2025 | Tryptyr |
| Bausch & Lomb Americas INC. | $162.54 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $151.35 | 2021-2023 | |
| Oyster Point Pharma, INC. | $136.59 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $136.52 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $92.19 | 2021-2024 | Cequa |
| Abbvie INC. | $83.54 | 2024-2025 | |
| Dompe US, INC. | $34.54 | 2024-2025 | Oxervate |
| Coopervision INC. | $33.75 | 2019-2024 | Myday Contact Lens |
| Harrow Eye, LLC | $32.51 | 2024 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.20 | 2020 | |
| Visioneering Technologies, INC. | $10.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Simpson Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.